Business Model Breakdown
How Stoke Therapeutics Inc Makes Money
STOK
Market Cap
$2.1B
Annual Revenue
$184M
Profit Margin
-3.7%
Employees
128
The Short Version
Stoke Therapeutics is a biotechnology company focused on developing RNA-based medicines to treat the underlying cause of severe genetic diseases. Their primary approach is through the proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which aims to increase protein expression to normalize function in conditions where too little protein is produced. Their lead product candidate, zorevunersen (STK-001), is in pivotal Phase 3 clinical trials for Dravet Syndrome, a severe form of epilepsy. Currently, the company generates revenue primarily from collaborations and grants, with significant future revenue expected to come from product sales if STK-001 receives regulatory approval.
Where the Revenue Comes From
Collaboration and grant revenue (variable, currently minor)
Future product sales of approved therapies (primary long-term revenue stream)
Who buys: Currently, clinical trial participants and collaborators. Post-approval, patients with rare genetic diseases (starting with Dravet Syndrome), their healthcare providers, and payers.
Why It Works (Competitive Advantages)
- ✔Proprietary TANGO platform for targeted gene augmentation.
- ✔STK-001's novel mechanism addressing the root cause of Dravet Syndrome.
- ✔Orphan drug designation for STK-001 providing market exclusivity.
Economic Moat: Narrow (Intangible Assets/IP (proprietary TANGO platform and drug candidates), Switching Costs (for patients who respond well to treatment, though not fully established yet))
What Our Analysis Says
DVR Score as of May 4, 2026
Stoke Therapeutics maintains a strong investment profile for 10x growth potential within 3-5 years, leveraging its innovative TANGO platform for rare genetic diseases. The advancement of STK-001 for Dravet Syndrome into pivotal Phase 3, with enrollment completion expected in Q2 2026 and data in mid-2027, continues to de-risk the lead asset. The company's financial health is robust, supported by approximately $390M in cash and a runway into mid-2028, aligning with its clinical development timeline. While still pre-profitability, which is typical for its stage, clear catalysts and strong analyst sentiment underscore its future market leadership potential and expanding competitive moat. Execution on key milestones remains consistent, warranting a slightly reinforced score.